Skip to main content

MDS 2017

  • Day 1
  • Day 2
  • Day 3
  • Day 4
  • Agenda

CMML: Current Management and Investigational Approaches

May 5, 2017August 13, 2017 liorco70

http://d22fjzb79sfamb.cloudfront.net/MDS2017/thu/1700%20-%201830/Thu%2017%EF%80%A240.mp4

Eric Padron (USA)

Post navigation

Risk assessment in CMML
Hypomethylating agent (HMA) therapy use and survival in older patients with Chronic Myelomonocytic Leukemia (CMML) in the United States: A large population-based study

Day 2

Plenary Session: MDS BIOLOGY AND PATHOGENESIS 1

  • 08:20 Elli Papaemmanuil (United Kingdom)

Plenary Session: MDS BIOLOGY AND PATHOGENESIS 2

  • 10:00 David P. Steensma (USA)
  • 10:20 Seishi Ogawa (Japan)
  • 10:40 Alan F. List (USA)

Plenary Session: DIAGNOSIS AND PROGNOSIS OF MDS / NEW CHALLENGES & NEW APPROACHES

  • 11:30 U. Germing (Germany)
  • 11:50 Francesc SolĂ© (Spain)
  • 12:10 Rafael Bejar (USA)
  • 12:30 D. Sallman (USA)
  • 12:45 R. Itzykson (France)

Plenary Session: BIOLOGY AND MANAGEMENT OF CMML

  • 17:00 Eric Solary (France)
  • 17:20 Luca Malcovati (Italy)
  • 17:40 Eric Padron (USA)
  • 18:00 A. Zeidan (USA)
  • 18:15 L. Drevon (France)
sparkling Theme by Colorlib Powered by WordPress